Annual Drug Patent Expirations for XELJANZ+XR
Xeljanz Xr is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. There are nine patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for XELJANZ XR.
This drug has two hundred and sixteen patent family members in sixty countries.
The generic ingredient in XELJANZ XR is tofacitinib citrate. Two suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
